We previously identified a rearrangement of mixed-lineage leukemia (MLL) gene (also known as ALL-1, HRX, and HTRX1), consisting of an in-frame partial tandem duplication (PTD) of exons 5 through 11 in the absence of a partner gene, occurring in approximately 4%-7% of patients with acute myeloid leukemia (AML) and normal cytogenetics, and associated with a poor prognosis. The mechanism by which the MLL PTD contributes to aberrant hematopoiesis and/or leukemia is unknown. To examine this, we generated a mouse knockin model in which exons 5 through 11 of the murine Mll gene were targeted to intron 4 of the endogenous Mll locus. Mll PTD/WT mice exhibit an alteration in the boundaries of normal homeobox (Hox) gene expression during embryogenesis, resulting in axial skeletal defects and increased numbers of hematopoietic progenitor cells. Mll PTD/WT mice overexpress Hoxa7, Hoxa9, and Hoxa10 in spleen, BM, and blood. An increase in histone H3/H4 acetylation and histone H3 lysine 4 (Lys4) methylation within the Hoxa7 and Hoxa9 promoters provides an epigenetic mechanism by which this overexpression occurs in vivo and an etiologic role for MLL PTD gain of function in the genesis of AML.
Introduction

Mixed-lineage leukemia (MLL, also known as ALL-1, HRX, or HTRX1)
is the human homolog of Drosophila Trx and is a maintenance factor for the homeobox (Hox) group of proteins, which play an important role in specifying cell fate during development and hematopoiesis (1) . Approximately 4% of patients with de novo acute myeloid leukemia (AML) have balanced translocations or insertions that result in fusion of MLL at chromosome 11q23 with 1 of over 40 functionally divergent genes. Although a central mechanism responsible for malignant transformation as a result of these chromosomal translocations involving 11q23 is lacking, the N terminus of MLL, which contains the AT-hook DNA-binding motif and a region homologous to DNA methyltransferase, is always retained in the fusion protein while the C terminus, which contains the activation and SET domains, is always replaced by the fusion partner (2) .
We discovered a rearrangement of MLL in AML patients whereby MLL is not fused with a partner gene but rather is consistently elongated with an in-frame partial tandem duplication (PTD) of exons 11-5 or 12-5 (former exon designations were 6-2 and 8-2) (3). In contrast with the myriad of MLL fusions in AML that result from chromosomal translocations, AML blasts with the MLL PTD retain the protein's C terminus, which contains the activation and SET domains and partially duplicates a region within the N terminus containing the AT-hook DNA-binding and repression domains (2) . Approximately 4%-7% of AML patients with normal cytogenetics harbor the MLL PTD and carry an especially poor prognosis (4, 5) .
HoxA genes are frequently overexpressed in leukemia (6) . The mechanism by which the MLL PTD contributes to aberrant hematopoiesis and/or leukemogenesis is currently unknown, but given MLL's role as a maintenance factor for Hox proteins, 1 mechanism could involve deregulation of Hox gene expression. In in vitro model systems, WT MLL regulates certain HOX gene expression via epigenetic modification at cis-regulatory regions, i.e., histone H3/H4 acetylation and H3 lysine 4 (Lys4) methylation, the latter of which requires MLL's C terminus SET domain (7, 8) . When the MLL-AF9 fusion gene (the result of one of the most common MLL rearrangements) is transduced into Mll -/-cells, Hoxa9 is overexpressed by an unknown mechanism that does not require binding of the MLL-AF9 fusion directly to the Hoxa9 promoter (8) . However, in another in vitro study, transduction of the MLL-eleven nineteen leukemia and the MLL-FK506-binding protein fusions into Mll WT/WT cells increased Hoxa9 expression via H3 acetylation but without increased H3 Lys4 methylation (9) . Likewise, when the Mll-AF9 fusion was knocked in as an endogenous allele, mice showed Hoxa9 overexpression and developed AML, but no epigenetic or other alteration could account for this overexpression (10, 11) . This suggests distinct mechanisms for induction of HOX genes by WT MLL and fusions of MLL resulting from balanced chromosomal translocations.
Taspase 1 cleaves the approximately 430-kDa MLL protein into 2 smaller components, and this cleavage has been shown to be essential for normal MLL function and regulation. Absence or downregulation of taspase 1 leads to absence or decreases in transcription of normal downstream targets of MLL, such as the Hox genes (12) . In virtually all cases involving reciprocal MLL translocations, the consensus sequences for taspase 1 are lost and replaced by the fusion partner, resulting in one of the only known common features among all the reciprocal translocations involving MLL. However, the MLL PTD differs from translocations in that the consensus sequences for taspase 1 are retained and the MLL PTD protein is cleaved (13) . How these MLL mutations function with or without taspase 1 cleavage is currently unsolved but highlights another important difference between MLL fusions and the MLL PTD.
In this study, we created a mouse expressing the Mll PTD off of the endogenous Mll promoter and examined the molecular basis for its phenotype. We show that this mouse has overexpression of certain HoxA genes, axial skeletal defects, and aberrant hematopoiesis, all compared with age- and sex-matched littermate controls. We also show that the Mll PTD is associated with increased histone H3/H4 acetylation and methylation of H3 Lys4 at cis-regulatory HoxA sequences, providing what we believe to be the first in vivo evidence for a mechanism by which an MLL gene rearrangement can directly alter HoxA gene expression.
Results
Mll PTD/WT mice are viable and express the fusion transcript. To study the in vivo consequences of the Mll PTD and to more closely model the monoallelic involvement seen in human AML with the MLL PTD (14), we employed homologous recombination in ES cells to introduce a genomic fragment containing exons 5 through 11 into intron 4 of Mll (Figure 1 ). Using 2 Mll PTD/WT (+) ES clones, we obtained 11 mice with germline transmission of the Mll PTD and backcrossed these mice with C57BL/6J mice to obtain Mll PTD/WT mice on a pure (congenic) C57BL/6J background. Southern blotting ( Figure 2A ) and DNA PCR (not shown) verified the presence of the Mll PTD/WT genotype. Southern blotting on 1-day-old pups from 5 matings also confirmed that Mll PTD/PTD homozygous mice are embryonic lethal (Table 1) . Sequencing of the RT-PCR product from Mll PTD/WT mice demonstrated a correctly spliced, in-frame fusion transcript confirming the precise targeting of exons 5 through 11 within intron 4 of the Mll locus ( Figure 2B ).
Absolute quantification of WT and PTD transcripts in
Mll PTD/WT mice using real-time RT-PCR. Real-time primers and probes were designed and optimized, amplifying the unique 11-5 Mll PTD fusion present only in Mll PTD/WT mice as well as the 14-15 Mll exon-exon junction located outside the duplicated region and common to both the Mll PTD allele and the Mll WT allele. Using these probes in an absolute quantification assay (13) , it was determined that the Mll PTD and Mll WT alleles were both expressed at low, near equivalent levels in the hematopoietic tissues of the Mll PTD/WT mice ( Figure 3 and Table 2 Generation of Mll PTD/WT mice. The backbone of the targeting vector is ploxPneo1 and contains a genomic clone spanning Mll intron 4 through intron 11. Linearization of the vector at a unique SfiI site within intron 4 allows for recombination at the germline intron 4 of Mll. A plasmid vector expressing Cre recombinase from a CMV promoter (pCre) was used to excise the neo cassette.
Figure 2
Germline transmission and verification of correct targeting in mice heterozygous for the Mll PTD. (A) Southern blot analysis using high molecular-weight DNA from spleens, digested with NdeI and hybridized to a probe that spans intron 4 and exon 5 of Mll (i4e5 in Figure 1 ). This generates a single WT band at 18 kb in Mll WT/WT mice, 2 bands representing 1 WT allele at 18 kb, and a band at 40 kb representing the rearranged allele in Mll PTD/WT mice. (B) The Mll PTD fusion transcript was amplified using an upstream primer from Mll exon 11 and a downstream primer from Mll exon 6 amplifying a single 335-bp unique fusion transcript in the Mll PTD/WT mouse (+) and is absent in the sample from the Mll WT/WT mouse (-). Sequencing of these PCR products from the Mll PTD/WT mice verified the presence of the exon 11-exon 5 fusion site. The 1-kb+ ladder was used to determine amplification size.
of Mll PTD/WT mice less than 1 year of age identified axial skeleton malformations, including a rudimentary or missing thirteenth rib, indicative of a T13→L1 transformation (70% penetrance, n = 13), and an S1 vertebral duplication, indicative of an S2→S1 transformation (63%, n = 11) (Figure 4 , B and C).
Given the WT Mll's role in maintaining Hox expression during development and the known association between HoxA expression, anteroposterior patterning, and posterior axis elongation, we examined Hoxa9 expression during embryogenesis. In situ hybridization performed on E12. Figure 6A) . A 5- to 20-fold increase in Mll PTD/WT spleen cells expressing the erythroid marker Ter119 was also noted, consistent with the observed increase in erythroid progenitor populations as measured by BFU-E ( Figure 6 , B and C). However, extensive phenotypic analyses performed as previously described (15) Figure 6 , G-H) but also showed a substantial amount (50%) of apoptosis ( Figure 6I ) such that absolute cell counts over this period of time were only modestly increased from the initiation of culture (Table 3 ). This near maintenance of homeostasis could also explain the normal cell counts observed in bone marrow, spleen, and blood of Mll PTD/WT mice in vivo. The lack of viable Mll WT/WT cells at day 18 in repeated assays (Table 3) precluded our ability to obtain statistically meaningful comparative data in repeated cultures. In contrast, Mll PTD/WT progenitor cells were sustained in liquid culture for more than 4 months.
Increased expression of HoxA genes in Mll PTD/WT mice. To establish a possible cause for the aberrant increases in both the number of primary colonies and increased proliferative capacity of replated progenitors from Mll PTD/WT mice, we quantified expression of Hoxa7, Hoxa9, and Hoxa10 within hematopoietic tissues. We found consistent and significant overexpression of each HoxA gene in BM, spleen, and blood when compared with their expression in matched Mll WT/WT littermate controls ( Figure 7 , A-C). Expression of Hoxa1, a HoxA family member that is not regulated by Mll, was unaltered in any of the hematopoietic tissues examined while Hoxc8, a HoxC family member that has been shown to be positively regulated by WT MLL (8), was also not upregulated in any of the tissues examined (not shown).
The lack of significant differences in cellular populations of blood, spleen, and BM between Mll PTD/WT and Mll WT/WT mice as noted above suggested that the increased HoxA gene expression was due to an increase in the HoxA expression on a per cell basis. To confirm this, we sorted equal numbers of cells from BM of Mll PTD/WT and Mll WT/WT mice expressing different lineage markers: B220, CD3, CD11b, Gr-1, and Ter119. RNA was isolated from an equivalent number of cells and reverse transcribed into cDNA. Using real-time RT-PCR, Hoxa9 was shown to be overexpressed in each of the Mll PTD/WT cell subsets when compared with the identical Mll WT/WT subset, consistent with an increase in HoxA gene expression on a per cell basis ( Figure 7D ). Epigenetic alterations at HoxA gene promoters in Mll PTD/WT mice. As noted earlier, HoxA gene overexpression has been noted in both in vitro and in vivo models of the MLL-AF9 fusion, but an in vivo mechanism to explain this upregulation in this or any MLL rearrangement associated with leukemia has yet to be provided (11) . Two groups have shown that WT MLL has intrinsic histone H3 Lys4 methyltransferase activity within its C terminus SET domain (7, 8) , which is retained in the MLL PTD. To test whether epigenetic modifications within HoxA promoters were responsible for HoxA overexpression in Mll PTD/WT hematopoietic tissues, chromatin immunoprecipitation (ChIP) was performed within promoter sequences known to be important for maintaining HoxA transcription and spleen and BM were compared with similar tissues in Mll WT/WT mice. Mll PTD/WT mice displayed an increase in histone H3 and H4 acetylation and H3 Lys4 methylation with a corresponding decrease in H3 Lys9 methylation within the Hoxa9 (Figure 8 , A and B) and Hoxa7 (not shown) promoters. These epigenetic modifications associated with gene transcription establish a mechanistic link between the Mll PTD/WT genotype and the associated overexpression of Mll targets Hoxa7 and Hoxa9. No such epigenetic changes were noted within the pertinent promoter region of Hoxa10.
We further assessed whether the increased histone modifications associated with gene activation were due to a gain of function of the Mll PTD and not the result of losing a WT Mll allele. H3/H4 acetylation and H3 Lys4 methylation at the Hoxa7 and Hoxa9 promoters were therefore measured using ChIP in combination with SyBR green real-time PCR in Mll PTD/WT and Mll WT/-BM and spleen and compared with similar measurements in Mll WT/WT BM and spleen. Results show no significant difference in the histone modifications at these promoters when comparing Mll WT/-and Mll WT/WT tissues. In contrast, Mll PTD/WT tissues showed significantly increased H3/H4 acetylation and H3 Lys4 methylation at the Hoxa7 and Hoxa9 promoters when compared with these other 2 genotypes (Figure 8 , C and D, and Absence of leukemic transformation in Mll PTD/WT mice highlights important requirement for second hit in the progression of leukemia. Despite the aberrant hematopoiesis, the mice had not developed leukemia over 2 years of observation. Hoxa9 cooperates with overexpressed Meis1 in the induction of murine AML (16) (17) (18) . We therefore quantified Meis1 transcript in affected hematopoietic tissues but found no evidence of overexpression (not shown). Likewise, we have noted that AML blasts from patients harboring the MLL PTD consistently lack expression of the WT MLL allele (13); however, hematopoietic tissues of Mll PTD/WT mice showed near equivalent levels of WT and PTD transcript ( Figure 2C ). Thus, it is possible that these and/or other additional molecular alterations are required for malignant transformation and can explain the aberrant hematopoiesis in the absence of leukemic transformation in Mll PTD/WT mice.
Discussion
In the current report, we describe a mouse engineered with Mll PTD expression driven by its endogenous promoter. The Mll PTD/PTD genotype appears embryonic lethal, and characterization of these embryos is ongoing. Mll PTD/WT mice are viable, are able to reproduce, and are without serious illness after 2 years of observation. However, Mll PTD/WT mice have a high penetrance of skeletal abnormalities that consist of a missing or rudimentary thirteenth rib and a duplication of the S1 vertebral body. Hematopoietic abnormalities consist of significantly increased BFU-E, GM-CFU, and GEMM-CFU progenitors in cultures from Mll PTD/WT splenocytes when compared with age- and sex-matched Mll WT/WT littermate controls. Alterations in members of the homeobox or Hox family of genes could reasonably explain these seemingly diverse phenotypic findings in the Mll PTD mice since certain Hox members are critical in axioskeletal and hematopoietic development and maintenance of Hox expression is positively regulated by WT Mll (1). The current report documents the increased expression of selected HoxA genes that is coincident with the Mll PTD and, for what we believe is the first time, provides a mechanism by which an Mll defect that is associated with AML causes deregulation of HoxA expression in vivo. Table 3 ), precluding a statistical comparison of these results in G-I.
Hox genes display spatiotemporal expression patterns that are colinear with respect to their location on the chromosome (19) . Thus, for normal skeletal development to proceed, Hox genes must be expressed in the right cell type at the right time. Expression of these genes at incorrect times or locations leads to disruptions in normal Hox expression boundaries, resulting in altered cell fate and misspecification of segment identities (20) (21) (22) . To determine whether the malformations of the axial skeletons of our Mll PTD/WT mice were associated with alterations in Hox expression boundaries, we performed whole-mount in situ hybridizations on E12.5 embryos and found the expression of Hoxa9 in the Mll PTD/WT embryos extended laterally in the somitic mesoderm when compared with Mll WT/WT littermate controls. This finding is consistent with other reports that have implicated Hoxa9 as an important gene for lumbosacral patterning (23) .
Restricted Hox expression is also vital for normal hematopoiesis, and deregulation in HoxA expression can result in aberrant hematopoiesis and malignant transformation (18, (24) (25) (26) (27) (28) (29) (30) . Following the observations of progenitor cell abnormalities in Mll PTD/WT spleen, we noted significant increases in Hoxa7, Hoxa9, and Hoxa10 transcripts in the spleen, BM, and blood of Mll PTD/WT mice when compared with Mll WT/WT littermate controls and with Mll WT/-mice. However, Hoxa1, a HoxA family member not regulated by Mll, showed no increase in its expression in tissues of the Mll PTD/WT mice. Likewise, Hoxc8, a member of the HoxC paralogous group that has been shown to be a direct target of MLL, was not increased within these tissues, indicating the specific effect of the Mll PTD on these HoxA genes. Further, as these HoxA family members are positively regulated by WT Mll, their consistent and significant overexpression in the tissues of Mll PTD/WT mice also suggests that the Mll PTD was operating in a gain-of-function fashion.
WT MLL has been shown to directly and indirectly modify histones at the promoters of certain HOX genes, thereby maintaining gene transcription (7, 8) . Histone modifications are associated with gene activation and repression (31) (32) (33) . Histone acetylation is the predominant modification associated with gene activation as well as histone H3 Lys4 methylation, while histone H3 Lys9 methylation corresponds with gene repression. Enzymes known as histone acetyltransferases, such as cAMP response element-binding protein-binding protein (CBP), are responsible for histone acetylation and associate with MLL in a complex via its C terminal transactivation domain, which is uniquely preserved in the MLL PTD (34) . There are genetic data showing evolutionarily conserved association of the MLL homolog Trx with Drosophila CBP in the fly, thus demonstrating the importance of this protein interaction (35) . Other complexes found within the MLL supercomplex function as either activators or repressors of transcription, some via acetylation (7, 8) . Examination of the histone acetylation states at Hoxa7 and Hoxa9 promoters in our study showed overacetylation of histone H3/H4 in spleen and BM of Mll PTD/WT mice, explaining at least 1 mechanism by which the Mll PTD is mediating HoxA overexpression. The specific complexes associating with the Mll PTD that are responsible for this observation and the direct or indirect mechanism by which this is accomplished have yet to be elucidated. Like the transactivation domain, the SET domain is also retained in the C terminus of the MLL PTD, again in contrast to all other MLL gene fusions found in AML. The SET domain of MLL has histone H3 Lys4 methyltransferase activity essential for maintaining Hox expression (7, 8) . We hypothesized that histone H3 Lys4 methylation might also contribute to upregulation of these HoxA genes. Indeed, ChIP experiments revealed a correlation between overexpression of both Hoxa7 and Hoxa9 transcript with increases of histone H3 Lys4 methylation at these promoters in Mll PTD/WT tissues. These data and the absence of such an increase in the same tissues of Mll WT/-mice support the notion that the Mll PTD has a direct gain-of-function role in transcriptional activation of these target genes.
In contrast, the retroviral infection of Mll -/-murine embryonic fibroblasts with the MLL-AF9 fusion (lacking the SET domain) did not result in comparable Hoxa9 promoter modifications despite overexpression of the Hoxa9 transcript (7, 8) . Transductions using the MLL-eleven nineteen leukemia and MLL-FK506-binding protein fusions demonstrated binding to HoxA promoters and increases in H3 acetylation but no corresponding increases in H3 Lys4 methylation (36) . These experiments suggest distinct mechanisms of action in which Hoxa9 is positively regulated by different MLL gene fusions. In addition, our ChIP experiments showed a correlation between the overexpression of Hoxa7 and Hoxa9 and a decrease in the repression-associated methylation of histone H3 Lys9 at each promoter; however, the domain and/or complex within the Mll PTD that is associated with this epigenetic modification is unknown. Interestingly, we did not find similar histone modifications at the Hoxa10 promoter, suggesting its mechanism of overexpression is distinct from those we observed in Hoxa7 and Hoxa9 in Mll PTD/WT mice.
Exactly how the associated aberrant epigenetic modifications come about is unknown but must be directly or indirectly related to the PTD itself. Several possible mechanisms are now conceivable with the recent evidence that WT MLL directly binds to the promoter of these HoxA target genes, together with its supercomplex of repressing and activating proteins (7, 8) . The duplication of the DNA-binding AT-hook DNA-binding domain within the Mll PTD may have conferred sustained and therefore excessive binding and increased activation at the relevant Hoxa7 and Hoxa9 promoters or could in some way enhance the recruitment of the Mll PTD and its supercomplex to its target genes (37) . Alternatively, the associated supercomplex of activating and repressing components may be altered by the PTD in a way that changes a critical balance between these various complexes, excessively favoring target gene activation. It is conceivable that the binding of the Mll PTD to the promoter of these HoxA genes may interfere with the recruitment of the repression machinery. Careful biochemical characterization of these regulatory regions within the promoters of downstream targets of Mll will provide further insights into the dynamic regulation of these gene products in vivo.
Retroviral overexpression of Hox genes, including HoxA members, has been associated with massive deregulation of hematopoiesis and leukemia (27) . Despite the sometimes substantial overexpression of the same HoxA genes observed in our Mll PTD/WT mice, they displayed no signs of malignant transformation at 2 years of age. The increase in Mll PTD/WT progenitor cell number and proliferation during CFU and liquid culture assays, respectively, suggests that HoxA overexpression exerts its effect on immature cells of the hematopoietic compartment but by itself is insufficient to cause leukemic transformation. Overexpression of Hoxa7 or Hoxa9 rapidly induces AML in mice but requires forced coexpression of the Hox cofactor Meis1 (16) . Mll PTD/WT cells overexpressing Hoxa7 and Hoxa9 genes in our study did not display any increase in Meis1 transcript. Further, AML patients harboring the MLL PTD also undergo epigenetic silencing of their WT MLL allele in their leukemic blasts that contributes to enhanced cell survival (13) . Our Mll PTD mice express the WT Mll allele, presumably because this later event requires cooperation with other alterations. Finally, the MLL PTD has been shown to occur simultaneously with tyrosine kinase mutations in AML, such as the FLT3 ITD (38) and Rhe-PDGFRα fusion (39), neither of which has been detected in our Mll PTD/WT mice. Thus, the failure of our mice to develop frank leukemia is likely related to the absence of additional molecular aberrations that are critical for malignant transformation to occur in the presence of the Mll PTD.
While it would seem most logical that we are observing the earliest events in a continuum of how the Mll PTD contributes to the leukemic phenotype, it must also be considered that some or all of the abnormalities we have observed may not be related to the leukemogenic process as it occurs in patients with AML and the MLL PTD. For example, while the excessive production of erythroid and megakaryocytic progenitor populations is consistent with the specific role of Hoxa10 in these lineages (28) and with Hoxa10 overexpression found in the Mll PTD/WT mice, AML patients with the MLL PTD rarely have blasts of erythroid or megakaryocyte lineage. Clearly, additional work in combination with mice harboring other genetic defects, as described above, will need to be undertaken in order to shed light on the role of the Mll PTD in the genesis of leukemia.
In summary, we have engineered a mouse with the Mll PTD driven off of its endogenous promoter. We provide what we believe to be the first in vivo evidence for a mechanism by which an Mll gene fusion (in this case, a self fusion) strongly associated with AML leads to aberrant target gene activation, i.e., increased histone H3/ H4 acetylation and histone H3 Lys4 methylation.
Methods
All primers and primer/probe sets used, along with conditions of amplification can be found in Supplemental Tables 1 and 2 . Approximately 60 μg of the targeting vector was linearized within intron 4 of Mll using the unique SfiI restriction site and introduced into 3 × 10 7 R1 ES cells. A plasmid vector expressing Cre recombinase from a CMV promoter (pCre) that conferred puromycin resistance was transiently transfected into C186 Mll PTD/WT ES cells by electroporation. Cells were cultured overnight and then transferred to a selective media containing 1 μg/ml of puromycin, grown further, and subcloned. Following transient transfection, selection, and expansion, DNA-PCR was performed using an upstream primer from intron 11 and a downstream primer from the ploxPneo vector. This amplified a 0.9-kb band, suggesting that the pgkneo cassette had been removed, and this was confirmed by sequencing. Next, 2 independently targeted ES cell clones were selected for generating chimeric mice. After verifying that these clones were karyotypically normal and free of mycoplasma contamination, 15 ES cells from each clone were injected into 3.5-day-old blastocysts from pregnant C57BL/6 female mice (The Jackson Laboratory). Next, the chimeric embryos were transferred into pseudopregnant recipient Swiss-Webster female mice. Micromanipulations, blastocyst transfers, and generation of chimeric mice were performed at the Transgenic Shared Resource of The Ohio State University Comprehensive Cancer Center. Backcrossing to a pure C57BL/6 background was carried out in 5 generations using marker-assisted breeding (speed congenics) (The Jackson Laboratory).
Southern blot analysis. High molecular weight DNA extracted from cells was digested with SbfI and NdeI (New England Biolabs Inc.), and Southern blotting was performed according to previously described techniques (40) . DNA was transferred to Hybond N+ nitrocellulose membrane (Amersham Biosciences) and hybridized to a cDNA fragment spanning the Mll intron 4-exon 5 junction. The predicted fragment size for the Mll PTD allele was 40 kb while the predicted fragment size for the WT Mll allele was 18 kb.
Genotyping. DNA was prepared from tail biopsies of adult and newborn mice using standard phenol/chloroform extraction. DNA PCR was performed using a forward primer located within intron 6 and a reverse primer located within the targeting vector backbone that amplifies a 900-bp product. Total RNA was extracted from tissues using the RNeasy Mini Kit (QIAGEN), and RT-PCR was performed using MMLV Reverse Transcriptase (Invitrogen) with a forward primer located within exon 11 and a reverse primer located within exon 6, which resulted in the generation of a 335-bp PCR product. from n = 6-8 mice per genotype. Cells were then plated at a density of 2 × 10 4 cells/dish in M3434 methylcellulose (StemCell Technologies) to assess splenic progenitor populations. All colony assays were performed according to the manufacturer's protocol (StemCell Technologies). Secondary replating assays were enumerated and performed on day 14 of primary cultures. Cells were replated at a density of 10 4 cells/dish in M3434 methylcellulose (StemCell Technologies). Secondary cultures were also performed in liquid medium RPMI 1640 with GlutaMAX (Invitrogen) plus 100 ng/ml of stem cell factor, 10 ng/ml of mouse IL-3, and 20 ng/ml of human IL-6 (StemCell Technologies) and seeded simultaneously from primary CFU progenitor assays and in parallel with secondary replating assays at a density of 10 4 cells/ml.
ChIP. ChIP assays were performed using the Chromatin Immunoprecipitation Assay Kit (Upstate USA Inc.). Approximately 3 × 10 6 cells were used per assay, and approximately 1% of the extracted chromatin solution was saved for use as input DNA. Immunoprecipitation with the following antibodies was performed: anti-acetyl-Histone H4, anti-acetyl-Histone H3, anti-dimethyl-Histone H3 Lys4, and antidimethyl-Histone H3 Lys9 (Upstate USA Inc.). The DNA was extracted using phenol-chloroform, precipitated with ethanol, and dissolved in water. Immunoprecipitations were analyzed by nested PCR using GeneAmp PCR System 9700 (Applied Biosystems). The cycle number and the amount of template were optimized to ensure that results were within the linear range of amplification. The PCR products were size fractionated through 1.0% agarose/ethidium bromide gels.
Quantification of histone acetylation and methylation at Hoxa7 and Hoxa9 promoters in Mll PTD/WT , Mll WT/-(generously provided by the late S. Korsmeyer), and Mll WT/WT DNA extracted from spleen and BM cells was undertaken using real-time quantitative PCR with SyBR green incorporation (Applied Biosystems). Primers were designed and optimized to amplify genomic sequences in the Hoxa7 and Hoxa9 promoters (Supplemental Tables 1 and 2 ). Each reaction used 2 μl of DNA template and 12.5 μl SyBR Green PCR Master Mix (Applied Biosystems) and was normalized to input DNA. The specificity of PCR products was analyzed by addition of a melting curve cycle, which consisted of 1 cycle each of 60°C for 15 seconds, 95°C for 20 seconds, and 60°C for 15 seconds, followed by analysis on Dissociation Curve Analysis software, version 1.0 (Applied Biosystems).
Comparative real-time RT-PCR. Total RNA was extracted from mouse BM, spleen, and peripheral blood samples and cDNA prepared as previously described (41) . Primer and probe sets to detect murine Hoxa7, Hoxa9, and Hoxa10 transcripts were designed using Primer Express (Applied Biosystems). Real-time RT-PCR efficiency was optimized for each primer/probe set using established guidelines (User Bulletin, Applied Biosystems; http://www.appliedbiosystems.com/support/apptech/). Comparative real-time RT-PCR was performed following the manufacturer's suggested procedures and using the ABI Prism 7700 Sequence Detection System (Applied Biosystems). To normalize for RNA content, the r18s primer/probe set was included in multiplex reactions. Data were analyzed using SDS version 1.7a software (Applied Biosystems) and reported as 2 -ΔΔCt , which represents the fold differences when normalized to an internal control (r18s) and then compared with Mll WT/WT sibling control samples analyzed on the same 96-well plate. For cell-sorting real-time RT-PCR experiments, whole BM cells were harvested and stained with antibodies to Ter119, CD71, Gr-1, CD11b, B220, and CD3. A minimum of 1 × 10 5 cells positive for each lineage marker was isolated using a FACSVantage (BD). Equivalent numbers of cells positive for each marker from Mll WT/WT and Mll PTD/WT were used to quantify HoxA gene expression. Real-time RT-PCR was then performed as described above. We used our previously published methodology to quantify absolute levels of Mll PTD and Mll WT transcripts present in BM, spleen, and blood of Mll PTD/WT mice by real-time RT-PCR (13) . Further information on primers and probes is provided in Supplemental Methods.
Flow cytometric analysis for lineage and subset determination, proliferation, and apoptosis. Cell lineages and hematopoietic subsets within the BM, spleen, and peripheral blood were assessed using lineage-specific antibodies as previously described (15, 41) . Immunofluorescent analysis of antigen expression was performed using a FACSCalibur (BD) and CellQuest software (version 3.3; BD). For quantitative assessment of cellular proliferation, BrdU incorporation was measured according to the manufacturer's protocol (BD Biosciences - Pharmingen). To assess differences in apoptosis, annexin V and PI staining were used and performed according to manufacturer's protocol (BD Biosciences - Pharmingen).
Whole mount in situ. Whole mount in situ was performed on E12.5 embryos as previously described (1), using digoxygenin-labeled riboprobes generated according to manufacturer's protocols (Roche Diagnostics). Primer pairs used to generate both sense and anti-sense probes first standardized on WT embryos can be obtained in Supplemental Tables 1 and 2 .
Skeletal analysis. Intact skeletons were prepared using sex-matched Mll PTD/WT and Mll WT/WT mice 20 weeks of age using previously described methods (42) . The microCT images were performed as follows: the sacral vertebrae specimens were mounted in 50-ml plastic test tubes filled with glycerol and imaged at 32 kV, 1 mA, and 1-second exposure with image intensifier operating in 7-inch mode. The spatial resolution of the images is 60 μm.
Statistics. A Wilcoxon's signed-rank test was used to compare differences in CFU growth between the Mll WT/WT and Mll PTD/WT splenocytes. The Hoxa7, Hoxa9, and Hoxa10 expression levels for each tissue were compared between Mll WT/WT and Mll PTD/WT mice using a 2-sample 2-tailed Student's t test.
